Shire has announced a new collaboration with Rani Therapeutics that will focus on the development of a new approach to delivering haemophilia therapies.

The companies will work together to assess the benefits of Rani Pill technology for the oral delivery of factor VIII (FVIII) therapy for patients with haemophilia A, with Shire also making an equity investment in Rani Therapeutics as part of the agreement.

“Shire is partnering with Rani Therapeutics to assess the benefits of Rani Pill technology in the delivery of haemophilia A therapy.“

The Rani Pill is a capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it can enter the small intestine and deliver medication painlessly into the intestinal wall.

Under the terms of the deal, Shire will receive an exclusive option to negotiate a licence to develop and commercialise the technology for delivery of factor VIII therapy following the completion of feasibility studies. 

Fritz Scheiflinger, head of global research at Shire, said: "We are excited by the potential of this partnership to reduce the chronic burden of haemophilia on patients' everyday lives by researching an oral option to deliver FVIII to patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.